Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis

Skin Therapy Lett. 2019 Mar;24(2):1-3.


Hyperhidrosis is a condition characterized by excessive sweat production beyond which is physiologically necessary for thermal regulation. Affecting over 4.8% of the United States population, studies have shown that severe primary hyperhidrosis interferes with daily activities and can be considered intolerable, negatively impacting a patient’s quality of life. Glycopyrronium tosylate is a topical anticholinergic agent that reduces sweat production by blocking the activation of acetylcholine receptors in peripheral sweat glands. In clinical trials, topical glycopyrronium tosylate, a pre-moistened cloth containing 2.4% glycopyrronium solution, was shown to be an effective, safe and non-invasive treatment for patients suffering from primary hyperhidrosis. This review examines the clinical trials of topical glycopyrronium tosylate and its role in primary hyperhidrosis. Glycopyrronium tosylate was recently US FDA-approved (as of June 2018) to manage patients with primary axillary hyperhidrosis.

Keywords: anticholinergic; axillary hyperhidrosis; glycopyrronium tosylate; Qbrexza, sweat; treatment.

Publication types

  • Review

MeSH terms

  • Administration, Cutaneous
  • Cholinergic Antagonists / administration & dosage
  • Cholinergic Antagonists / therapeutic use*
  • Clinical Trials as Topic
  • Glycopyrrolate / administration & dosage
  • Glycopyrrolate / therapeutic use*
  • Humans
  • Hyperhidrosis / drug therapy*


  • Cholinergic Antagonists
  • glycopyrronium tosylate
  • Glycopyrrolate